Releases
NLTX
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Neoleukin Therapeutics (NLTX) stock and general news. This information may help you make smarter investment decisions.
About NLTX
Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.